China Universal Asset Management Co. Ltd. Buys 3,821 Shares of Exscientia plc (NASDAQ:EXAI)

China Universal Asset Management Co. Ltd. raised its stake in shares of Exscientia plc (NASDAQ:EXAI) by 66.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 9,576 shares of the company’s stock after purchasing an additional 3,821 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Exscientia were worth $47,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Novo Holdings A S bought a new stake in Exscientia during the 2nd quarter worth approximately $66,742,000. Bank of New York Mellon Corp increased its stake in shares of Exscientia by 108.8% in the second quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock worth $1,981,000 after purchasing an additional 202,377 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Exscientia during the 2nd quarter valued at $256,000. Federated Hermes Inc. purchased a new position in shares of Exscientia during the 2nd quarter valued at $115,000. Finally, International Assets Investment Management LLC purchased a new stake in Exscientia in the 3rd quarter worth $77,000. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Exscientia Stock Down 5.3 %

EXAI opened at $4.86 on Friday. The company has a market capitalization of $587.51 million, a PE ratio of -3.74 and a beta of 0.84. The firm has a 50-day simple moving average of $5.09 and a two-hundred day simple moving average of $5.07. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.06. Exscientia plc has a 52 week low of $3.80 and a 52 week high of $7.91.

Exscientia (NASDAQ:EXAI) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The firm had revenue of $5.60 million for the quarter. Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. Analysts forecast that Exscientia plc will post -1.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EXAI has been the topic of several research analyst reports. TD Cowen restated a “hold” rating on shares of Exscientia in a research report on Friday, August 9th. Barclays restated an “equal weight” rating and issued a $5.00 price target on shares of Exscientia in a research note on Tuesday, August 13th.

Exscientia Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.